NCT00955981View on ClinicalTrials.gov

Gout Dose Response Study

PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

September 30, 2011

Conditions
Hyperuricemia
Interventions
DRUG

RDEA594

Uricosuric agent for the treatment of gout

DRUG

Placebo

Matching placebo

Trial Locations (29)

1233

Sofia

1709

Sofia

4002

Plovdiv

Plovidv

5800

Pleven

9010

Varna

22143

Hamburg

27103

Winston-Salem

32720

DeLand

38305

Jackson

47574

Goch

90017

Los Angeles

90402

Nuremberg

V3K 3P4

Coquitlam

V1Y8E7

Kelowna

L4J6W6

Thornhill

M9W 4L6

Toronto

J7J 2K8

Mirabel

792 01

Bruntál

140 00

Prague

148 00

Prague

0102

Tbilisi

0186

Tbilisi

82-300

Elblag

90-153

Lodz

20-607

Lublin

61-289

Poznan

26-610

Radom

53-025

Wroclaw

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY

NCT00955981 - Gout Dose Response Study | Biotech Hunter | Biotech Hunter